Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study for prevention of erlotinib-induced cutaneous rash
2012-002793-30Phase 2Terminated
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fondazione IRCCS San Gerardo dei Tintori. Primary endpoint: Incidence of cutaneous rash grade >2 within first 30 days. Started Mar 2013; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-002793-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002793-30.